Zymeworks (ZYME) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zymeworks Inc., a clinical-stage biotech company, is slated to present at the TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference in March 2024. These conferences will feature one-on-one meetings and discussions showcasing Zymeworks’ advancements in biotherapeutics for challenging diseases, including their lead product candidate, zanidatamab. The events will be accessible via webcasts on the company’s investor relations website.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.